Shanghai Escugen Biotechnology Co., Ltd

Quick facts

Phase 2 pipeline

• ESG206 · Diabetes
  ESG206 is a small molecule targeting the SGLT2 receptor.

Phase 1 pipeline

• ESG406

Competitive intelligence

For the full portfolio CI brief — phase mix, recent regulatory actions, upcoming PDUFA dates, patent timeline, class-overlap with competitors:

• Shanghai Escugen Biotechnology Co., Ltd portfolio CI brief
• Shanghai Escugen Biotechnology Co., Ltd pipeline updates RSS